Welcome to our dedicated page for Scpharmaceutical news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on Scpharmaceutical stock.
scPharmaceuticals Inc. (formerly traded on Nasdaq under the symbol SCPH) generated a steady stream of company-specific news before and during its acquisition by MannKind Corporation. Public announcements and SEC filings show that scPharmaceuticals focused on cardiorenal healthcare, with news often centered on FUROSCIX, a subcutaneous furosemide injection indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including nephrotic syndrome.
News coverage for scPharmaceuticals has included product and clinical updates, such as FDA approval of an expanded FUROSCIX indication to include chronic kidney disease and the formal launch of FUROSCIX into that market. The company also reported progress on its SCP-111 furosemide formulation and related autoinjector program, including multiple Notices of Allowance from the U.S. Patent and Trademark Office for patents covering SCP-111 and plans for supplemental NDA submissions.
Financial and corporate updates have been another major theme. scPharmaceuticals regularly issued press releases on quarterly and annual financial results, highlighting net FUROSCIX revenues, dose volumes, prescriber adoption, and expansion into integrated delivery networks. Additional news detailed participation in investor conferences, financing arrangements, and credit facilities.
A key set of news items in 2025 described MannKind’s agreement to acquire scPharmaceuticals, the tender offer terms, and the strategic rationale around cardiorenal and cardiometabolic care. Subsequent releases and a Form 8-K dated October 7, 2025 confirmed completion of the tender offer and merger, after which scPharmaceuticals became a wholly owned subsidiary of MannKind and its shares were delisted from Nasdaq. This news page therefore serves as an archive of historical announcements, from product and regulatory milestones to the transaction that ended SCPH’s life as an independent public stock.
scPharmaceuticals (SCPH) has received FDA approval for its supplemental New Drug Application (sNDA) to expand FUROSCIX® indication to include treating edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025.
FUROSCIX is a subcutaneous injection containing 80 mg/10 mL furosemide, designed for treating edema in patients with chronic heart failure or CKD. The approval represents a significant expansion of the treatment options for patients experiencing acute fluid overload, potentially enabling them to receive treatment at home rather than requiring hospitalization.
The company has prepared for the launch through key opinion leader engagement, market research, and commercial readiness initiatives. Safety considerations include monitoring for fluid, electrolyte, and metabolic abnormalities, particularly in elderly patients and those receiving higher doses. The most common adverse reactions reported in clinical trials were site and skin reactions.
scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company focused on cardiorenal healthcare innovation, has announced its participation in two major investor conferences in March 2025. John Tucker, President and CEO, will represent the company at both events.
The scheduled appearances include:
- A fireside chat at the 45th Annual TD Cowen Healthcare Conference on March 5 at 11:10AM ET
- A corporate presentation at the Leerink Partners 2025 Global Healthcare Conference on March 11 at 2:20PM ET
Both presentations will be accessible via webcast through the company's website under the Investor Relations section.
scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company focused on revolutionizing cardiorenal healthcare through patient-centric innovations, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
John Tucker, President & Chief Executive Officer, will deliver a presentation on Wednesday, February 12 at 2:40PM ET. The presentation will be accessible via webcast through the company's website under the Investor Relations section's 'News & Events' tab.
scPharmaceuticals (SCPH) reported strong preliminary Q4 2024 results, with expected net revenue between $12-12.3 million, representing 99% growth over Q4 2023. The company's full-year 2024 net revenue is anticipated to reach $36.2-36.5 million, up 167% from 2023's $13.6 million.
Q4 2024 highlights include approximately 13,300 FUROSCIX doses shipped, a 23% increase from Q3's 10,800 doses. The gross-to-net discount is expected to be 18-19%, compared to 15.7% in Q3 2024. The company ended 2024 with approximately $75.7 million in cash and cash equivalents, with accounts receivable increasing 27% from September 2024.
SCPH expanded its distribution network by adding a specialty pharmacy and anticipates growth in 2025 through Medicare redesign implementation and a potential FUROSCIX indication expansion for chronic kidney disease patients in March.
scPharmaceuticals reported strong Q3 2024 results with FUROSCIX net revenue of $10.0 million, up 164% from Q3 2023 and 24% from Q2 2024. Key achievements include FDA approval for NYHA Class IV patients, positive PK/PD data for Autoinjector program, and completion of $175 million financing. The company filled approximately 10,800 FUROSCIX doses (+16% QoQ) and expanded to 3,100 unique prescribers. However, gross-to-net discount increased to 15.7% from 8% in Q2. The company reported a net loss of $35.1 million ($0.75 per share), with $91.5 million cash on hand as of quarter-end.
scPharmaceuticals (Nasdaq: SCPH) announced it will release its third quarter 2024 financial results on Wednesday, November 13, 2024. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss financial results and provide a business update. Participants can join via phone using domestic (1-877-407-9208) or international (1-201-493-6784) numbers with conference code 13749995. A webcast and replay will be available through the company's website.
scPharmaceuticals Inc. (Nasdaq: SCPH) has announced a Key Opinion Leader (KOL) webinar scheduled for October 22, 2024, at 1:00 PM ET. The webinar will focus on a nephrologist's perspective on using FUROSCIX for treating fluid overload in heart failure and its potential use in chronic kidney disease (CKD) patients.
The event will feature Dr. Michael Aaronson from Lincoln Nephrology and Hypertension. The FDA has set a PDUFA target action date of March 6, 2025, for scPharmaceuticals' Supplemental New Drug Application (sNDA) to expand FUROSCIX's indication to include CKD-related fluid overload treatment.
scPharmaceuticals' management will provide updates on long-term growth initiatives, including the FDA-approved expansion of FUROSCIX for NYHA Class IV heart failure patients and the development of a low volume autoinjector. A live Q&A session will follow the presentation.
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company specializing in optimized delivery of infused therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. John Tucker, the company's President & CEO, is scheduled to present on Wednesday, September 11 at 10:00AM ET.
In addition to the presentation, Mr. Tucker will be engaging in investor meetings throughout the day. Interested parties can access a webcast of the presentation via a provided link or through the 'News & Events' section of scPharmaceuticals' official website.
This event provides an opportunity for scPharmaceuticals to showcase its progress in developing products aimed at advancing patient care and reducing healthcare costs through innovative infusion therapy delivery methods.
scPharmaceuticals Inc. (Nasdaq: SCPH) reported strong Q2 2024 financial results and business updates. Key highlights include:
- Net FUROSCIX revenue of $8.1 million, up 33% sequentially from Q1
- Approximately 9,300 FUROSCIX doses filled, a 15% increase from Q1
- Completed financings of up to $175 million, extending cash runway through expected profitability
- FDA approval to expand FUROSCIX indication for NYHA Class IV chronic heart failure patients
- Positive topline PK/PD data for FUROSCIX autoinjector
- FDA acceptance of sNDA for FUROSCIX label expansion to include CKD patients
The company's focus on commercial growth and lifecycle management initiatives positions FUROSCIX as a key part of a new heart failure treatment paradigm.
scPharmaceuticals Inc. (Nasdaq: SCPH) has announced the pricing of a public offering of 12,000,000 shares of common stock at $4.00 per share and pre-funded warrants for up to 500,000 shares at $3.999 per underlying share. The offering aims to raise approximately $50.0 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares. The offering, expected to close on August 13, 2024, is being made pursuant to a shelf registration statement. Leerink Partners and TD Cowen are acting as joint book-running managers, with Craig-Hallum as lead manager and Maxim as manager.